| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRNa5 |
| Uniprot No | P30532 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 38-131aa |
| 氨基酸序列 | SEPSSIAKHEDSLLKDLFQDYERWVRPVEHLNDKIKIKFGLAISQLVDVD EKNQLMTTNVWLKQEWIDVKLRWNPDDYGGIKVIRVPSDSVWTP |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRNα5(烟碱型乙酰胆碱受体α5亚基)重组蛋白的3篇代表性文献示例(内容基于典型研究方向概括，非真实文献)：
1. **文献名称**：*Structural Insights into the Human CHRNA5 Nicotinic Receptor Subunit through Recombinant Protein Expression*
**作者**：Smith J, et al.
**摘要**：通过大肠杆菌表达系统成功获得重组CHRNA5胞外结构域蛋白，利用X射线晶体学解析其三维结构，揭示其与尼古丁结合的潜在位点及与其他受体亚基的相互作用机制。
2. **文献名称**：*Functional Characterization of CHRNA5 Recombinant Protein in Nicotine Dependence*
**作者**：Lee S, et al.
**摘要**：在HEK293细胞中表达重组CHRNA5蛋白，结合电生理学实验证明其与β2亚基共表达时增强尼古丁诱导的电流反应，提示CHRNA5在尼古丁成瘾中的调控作用。
3. **文献名称**：*CHRNA5 Genetic Variants and Recombinant Protein Analysis in Lung Cancer Risk*
**作者**：Wang H, et al.
**摘要**：通过构建CHRNA5重组蛋白(包含常见SNP rs16969968突变体)，发现特定突变导致受体对尼古丁代谢物的敏感性改变，可能解释其与肺癌风险的遗传关联。
4. **文献名称**：*Development of a High-Throughput Assay Using CHRNA5 Recombinant Protein for Drug Discovery*
**作者**：Garcia R, et al.
**摘要**：利用昆虫细胞系统表达纯化CHRNA5重组蛋白，建立基于荧光标记的配体竞争结合实验，筛选出新型化合物可选择性调控α5-containing受体活性，为治疗神经疾病提供候选分子。
**提示**：实际文献需通过PubMed或Google Scholar检索关键词(如“CHRNA5 recombinant protein”“nicotinic receptor α5 expression”)获取，并核实作者及期刊信息。
The CHRNA5 recombinant protein is derived from the CHRNA5 gene, which encodes the alpha-5 subunit of the nicotinic acetylcholine receptor (nAChR). nAChRs are ligand-gated ion channels critical for synaptic transmission in the central and peripheral nervous systems. The alpha-5 subunit, while not directly participating in acetylcholine binding, modulates receptor function by influencing ion channel properties and receptor sensitivity. It typically combines with alpha-3 and beta-4 subunits (forming α3β4α5 nAChRs) in neuronal tissues, playing roles in neurotransmitter release, cognitive processes, and addiction pathways.
CHRNA5 has garnered significant attention due to its association with nicotine dependence, lung cancer susceptibility, and chronic obstructive pulmonary disease (COPD). Genetic variants, such as the single nucleotide polymorphism (SNP) rs16969968 in CHRNA5. are linked to altered nicotine receptor activity and increased addiction risk. Recombinant CHRNA5 protein is produced via heterologous expression systems (e.g., mammalian cells, insect cells) to study its structural and functional roles. This engineered protein retains key domains, including the extracellular ligand-binding region, transmembrane ion channel, and intracellular regulatory sites, enabling in vitro investigations into receptor assembly, ligand interactions, and signaling mechanisms.
Researchers utilize CHRNA5 recombinant protein to screen therapeutic compounds targeting nAChR-related disorders, including smoking cessation drugs and neuroprotective agents. Its production often involves affinity purification and validation via Western blotting or functional assays (e.g., electrophysiology). Studies using this protein have clarified mechanisms underlying nicotine addiction and identified potential biomarkers for cancer risk. Despite challenges in maintaining native conformational stability during recombinant production, CHRNA5 remains a vital tool for advancing neuropharmacology and precision medicine.
×
